Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Untreated Metastatic RCC and Sarcomatoid Features
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Atezolizumab Plus Bevacizumab Versus Sunitinib for Patients With Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial
Eur Urol Oncol 2020 Jul 09;[EPub Ahead of Print], BI Rini, RJ Motzer, T Powles, DF McDermott, B Escudier, F Donskov, R Hawkins, S Bracarda, J Bedke, U De Giorgi, C Porta, A Ravaud, F Parnis, E Grande, W Zhang, M Huseni, S Carroll, R Sufan, C Schiff, MB AtkinsFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.